Literature DB >> 31648814

The Editor's I on Disease Development.

Mamta Jain1, Michael F Jantsch2, Konstantin Licht1.   

Abstract

Adenosine-to-inosine (A-to-I) editing of RNA leads to deamination of adenosine to inosine. Inosine is interpreted as guanosine by the cellular machinery, thus altering the coding, folding, splicing, or transport of transcripts. A-to-I editing is tightly regulated. Altered editing has severe consequences for human health and can cause interferonopathies, neurological disorders, and cardiovascular disease, as well as impacting on cancer progression. ADAR1-mediated RNA editing plays an important role in antiviral immunity and is essential for distinguishing between endogenous and viral RNA, thereby preventing autoimmune disorders. Interestingly, A-to-I editing can be used not only to correct genomic mutations at the RNA level but also to modulate tumor antigenicity with large therapeutic potential. We highlight recent developments in the field, focusing on cancer and other human diseases.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  ADAR; RNA editing; RNA therapeutics; cancer; innate immunity; neurodegenerative disease

Mesh:

Substances:

Year:  2019        PMID: 31648814     DOI: 10.1016/j.tig.2019.09.004

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  19 in total

1.  Harnessing Nature's Molecular Recognition Capabilities to Map and Study RNA Modifications.

Authors:  Ansley S Felix; Alexandria L Quillin; Shikufa Mousavi; Jennifer M Heemstra
Journal:  Acc Chem Res       Date:  2022-07-28       Impact factor: 24.466

2.  Direct identification of A-to-I editing sites with nanopore native RNA sequencing.

Authors:  Jia Wei Joel Heng; Pornchai Kaewsapsak; Tram Anh Nguyen; Eng Piew Louis Kok; Dominik Stanojević; Hao Liu; Angelysia Cardilla; Albert Praditya; Zirong Yi; Mingwan Lin; Jong Ghut Ashley Aw; Yin Ying Ho; Kai Lay Esther Peh; Yuanming Wang; Qixing Zhong; Jacki Heraud-Farlow; Shifeng Xue; Bruno Reversade; Carl Walkley; Ying Swan Ho; Mile Šikić; Yue Wan; Meng How Tan
Journal:  Nat Methods       Date:  2022-06-13       Impact factor: 47.990

Review 3.  To protect and modify double-stranded RNA - the critical roles of ADARs in development, immunity and oncogenesis.

Authors:  Emily A Erdmann; Ananya Mahapatra; Priyanka Mukherjee; Boyoon Yang; Heather A Hundley
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-12-27       Impact factor: 8.250

Review 4.  The Regulation of RNA Modification Systems: The Next Frontier in Epitranscriptomics?

Authors:  Matthias R Schaefer
Journal:  Genes (Basel)       Date:  2021-02-26       Impact factor: 4.096

Review 5.  The role of RNA editing enzyme ADAR1 in human disease.

Authors:  Brian Song; Yusuke Shiromoto; Moeko Minakuchi; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-06-08       Impact factor: 9.957

6.  ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity.

Authors:  Xiaoting Wu; Lijun Wang; Kai Wang; Jin Li; Rui Chen; Xiaodong Wu; Gehui Ni; Chang Liu; Saumya Das; Joost P G Sluijter; Xinli Li; Junjie Xiao
Journal:  Mol Ther       Date:  2021-07-16       Impact factor: 11.454

Review 7.  Regulatory Mechanisms of the RNA Modification m6A and Significance in Brain Function in Health and Disease.

Authors:  Justine Mathoux; David C Henshall; Gary P Brennan
Journal:  Front Cell Neurosci       Date:  2021-05-19       Impact factor: 5.505

Review 8.  RNA editing in mesothelioma: a look forward.

Authors:  Ananya Hariharan; Suna Sun; Martin Wipplinger; Emanuela Felley-Bosco
Journal:  Open Biol       Date:  2020-10-14       Impact factor: 6.411

9.  Clinical Applications of RNA Editing Technology for the Early Detection of Cancer and Future Directions.

Authors:  Mujib Ullah; Asma Akbar; Gustavo Yannarelli
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 10.  Non-Coding RNA Editing in Cancer Pathogenesis.

Authors:  Giulia Romano; Michela Saviana; Patricia Le; Howard Li; Lavender Micalo; Giovanni Nigita; Mario Acunzo; Patrick Nana-Sinkam
Journal:  Cancers (Basel)       Date:  2020-07-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.